COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
-64%
5Y
-26%
10Y
-51%
Liabilities
+
3Y
+9%
5Y
+10%
10Y
-48%
Equity
+
3Y
-90%
5Y
-66%
10Y
-60%

Balance Sheet Decomposition
COSCIENS Biopharma Inc

23.9m
Assets
18.8m
Liabilities
23.9m
Assets
18.8m
Liabilities
Current Assets 13.8m
Cash & Short-Term Investments 8.5m
Receivables 1.6m
Other Current Assets 3.7m
Non-Current Assets 10m
PP&E 9.9m
Other Non-Current Assets 132k
Current Liabilities 4m
Accounts Payable 1m
Accrued Liabilities 918k
Other Current Liabilities 2m
Non-Current Liabilities 14.8m
Long-Term Debt 2m
Other Non-Current Liabilities 12.8m

Balance Sheet
COSCIENS Biopharma Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2001 Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
8
8
17
24
12
9
10
49
38
32
47
40
43
35
42
22
8
15
8
24
65
51
34
16
Cash
0
0
0
0
0
0
0
0
0
13
15
15
28
11
0
22
0
0
0
24
56
51
34
16
Cash Equivalents
8
8
17
24
12
9
10
49
38
19
32
24
15
24
42
0
8
15
8
0
10
0
0
0
Short-Term Investments
26
44
32
25
23
52
31
1
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Receivables
16
48
37
49
12
11
9
5
4
5
8
8
2
1
1
0
0
0
1
2
4
2
0
2
Accounts Receivables
12
20
33
43
10
7
6
3
2
5
8
7
2
1
1
0
0
0
0
1
1
0
0
2
Other Receivables
3
28
4
5
2
4
3
1
1
1
1
1
0
0
0
0
0
0
1
1
3
2
0
1
Inventory
5
10
13
18
6
5
5
3
4
3
4
4
0
0
0
0
1
0
1
0
0
0
4
3
Other Current Assets
1
2
5
6
111
26
4
4
3
1
2
2
1
0
0
0
1
1
1
1
2
3
0
2
Total Current Assets
56
112
104
120
164
102
60
62
49
44
60
53
46
36
42
23
9
16
11
28
71
56
11
24
PP&E Net
10
14
15
17
14
13
8
7
4
3
3
2
1
1
0
0
0
0
1
0
0
0
12
11
PP&E Gross
10
14
15
17
14
13
8
7
4
3
3
2
1
1
0
0
0
0
1
0
0
0
12
11
Accumulated Depreciation
2
4
7
10
10
12
6
6
10
10
11
12
12
10
0
5
3
2
1
1
1
1
8
9
Intangible Assets
1
57
51
63
41
37
30
24
17
3
2
1
1
0
0
0
0
0
0
0
1
0
0
0
Goodwill
14
15
47
72
10
10
11
10
10
10
10
10
10
9
8
8
9
8
8
9
8
0
0
0
Note Receivable
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
Long-Term Investments
0
0
0
0
0
57
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
4
12
11
19
191
5
15
6
6
1
1
1
2
1
0
1
4
0
0
0
0
0
0
0
Other Assets
14
15
47
72
10
10
11
10
10
10
10
10
10
9
8
8
9
8
8
9
8
0
0
0
Total Assets
84
N/A
211
+149%
228
+8%
290
+27%
420
+45%
224
-47%
123
-45%
108
-12%
86
-20%
61
-29%
75
+23%
68
-10%
59
-13%
47
-20%
52
+9%
32
-38%
22
-30%
25
+13%
20
-20%
37
+85%
80
+116%
56
-30%
24
-58%
35
+48%
Liabilities
Accounts Payable
11
17
26
24
4
7
11
10
8
6
8
7
5
3
4
2
1
1
1
1
1
2
0
2
Accrued Liabilities
4
6
10
9
3
3
5
3
4
3
4
4
2
2
0
1
2
1
1
1
2
2
1
2
Short-Term Debt
0
27
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
2
2
3
10
1
1
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
Other Current Liabilities
0
31
9
17
57
6
5
8
7
5
6
5
0
2
2
1
3
3
3
2
5
3
0
2
Total Current Liabilities
17
84
47
60
64
16
22
22
19
14
18
16
7
8
6
4
6
6
6
5
8
7
1
7
Long-Term Debt
7
6
27
53
30
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
Deferred Income Tax
0
22
20
20
9
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Minority Interest
12
16
23
29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
12
13
28
208
17
13
65
58
65
62
59
35
25
24
21
19
18
17
19
19
13
0
13
Total Liabilities
35
N/A
140
+301%
131
-7%
190
+45%
310
+63%
45
-86%
35
-22%
87
+150%
77
-11%
79
+3%
80
+1%
74
-7%
42
-43%
33
-22%
30
-9%
25
-15%
25
-2%
23
-8%
22
-3%
24
+6%
27
+14%
20
-25%
3
-87%
22
+708%
Equity
Common Stock
61
98
145
157
130
169
31
31
41
61
102
123
134
151
205
214
222
222
225
235
293
293
14
22
Retained Earnings
12
29
56
66
43
10
43
103
128
161
189
213
204
222
272
298
314
310
317
310
330
347
4
12
Additional Paid In Capital
0
1
6
7
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
Other Equity
0
1
3
1
22
21
101
94
93
82
83
84
87
86
89
90
89
89
90
89
89
89
1
1
Total Equity
49
N/A
70
+42%
97
+39%
100
+3%
110
+10%
179
+63%
89
-50%
22
-76%
9
-57%
18
N/A
5
+74%
7
-49%
17
N/A
15
-15%
22
+49%
6
-71%
3
N/A
2
N/A
3
N/A
13
N/A
53
+302%
36
-32%
21
-41%
13
-37%
Total Liabilities & Equity
84
N/A
211
+149%
228
+8%
290
+27%
420
+45%
224
-47%
123
-45%
108
-12%
86
-20%
61
-29%
75
+23%
68
-10%
59
-13%
47
-20%
52
+9%
32
-38%
22
-30%
25
+13%
20
-20%
37
+85%
80
+116%
56
-30%
24
-58%
35
+48%
Shares Outstanding
Common Shares Outstanding
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
3
5
5
2
3

See Also

Summary
CSCI intrinsic value, competitors valuation, and company profile.
DCF Valuation
CSCI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CSCI stock valuation using valuation multiples.
Wall Street Estimates
CSCI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CSCI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 303,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.